L&K Biomed Balance Sheet Health
Financial Health criteria checks 5/6
L&K Biomed has a total shareholder equity of ₩30.6B and total debt of ₩11.8B, which brings its debt-to-equity ratio to 38.7%. Its total assets and total liabilities are ₩62.8B and ₩32.2B respectively. L&K Biomed's EBIT is ₩2.0B making its interest coverage ratio 1.3. It has cash and short-term investments of ₩12.8B.
Key information
38.7%
Debt to equity ratio
₩11.84b
Debt
| Interest coverage ratio | 1.3x |
| Cash | ₩12.78b |
| Equity | ₩30.59b |
| Total liabilities | ₩32.18b |
| Total assets | ₩62.76b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A156100's short term assets (₩44.4B) exceed its short term liabilities (₩22.8B).
Long Term Liabilities: A156100's short term assets (₩44.4B) exceed its long term liabilities (₩9.4B).
Debt to Equity History and Analysis
Debt Level: A156100 has more cash than its total debt.
Reducing Debt: A156100's debt to equity ratio has reduced from 46.4% to 38.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A156100 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if A156100 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.